Vera Therapeutics (VERA) CRO sells 2,187 shares to cover RSU tax withholding

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vera Therapeutics, Inc. Chief Regulatory Officer William D. Turner reported an open-market sale of 2,187 shares of Class A common stock at a weighted-average price of $41.9839 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations from vesting restricted stock units under the company’s equity incentive plans and did not represent a discretionary trade by Turner. The trades to satisfy withholding occurred over two business days, from February 23 to February 24, 2026. After these transactions, Turner beneficially owned 45,313 shares of Class A common stock.

Insights

Routine tax withholding sale; limited signal for investors.

The filing shows 2,187 shares of Vera Therapeutics Class A common stock sold at a weighted-average price of $41.9839 per share. The footnotes state the sales were mandated to cover tax withholding on vesting restricted stock units, under the company’s equity plans.

Because the transactions were "sell-to-cover" and not discretionary, they mainly reflect tax obligations rather than a change in the insider’s view of the company. Turner continues to hold 45,313 shares following the sales, indicating a continuing equity stake.

This type of non-discretionary sale is common around equity award vesting dates and is generally viewed as administrative. Future company filings may provide additional context on ongoing equity compensation and insider holdings over time.

Insider Trade Summary

Net Seller: 2,187 shares ($91,819)

Net Sell 1 txn

Insider Turner William D.

Role Chief Regulatory Officer

Sold 2,187 shs ($92K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	2,187	$41.9839	$92K

Holdings After Transaction: Class A Common Stock — 45,313 shares (Direct)

Footnotes (1)

The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

02/25/2026 - 07:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turner William D.

(Last)

(First)

(Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/23/2026⁽¹⁾	02/24/2026	S⁽²⁾		2,187	D	$41.9839⁽³⁾	45,313	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026.

2. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person.

3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

	/s/ Joseph R. Young, Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Vera Therapeutics (VERA) insider William D. Turner report on this Form 4?

He reported selling 2,187 shares of Vera Therapeutics Class A common stock. The sale was linked to tax withholding obligations from vesting restricted stock units, rather than a discretionary decision to reduce his investment position in the company.

Was the Vera Therapeutics (VERA) insider stock sale a discretionary trade?

No. The filing states the shares were sold solely to satisfy tax withholding obligations on RSU vesting. The sale was mandated under Vera Therapeutics’ equity incentive plans via a “sell-to-cover” arrangement, not a voluntary trade by the Chief Regulatory Officer.

How many Vera Therapeutics (VERA) shares did William D. Turner sell and at what price?

He sold 2,187 shares of Class A common stock at a weighted-average price of $41.9839 per share. Footnotes explain the shares were sold in multiple transactions between $41.005 and $42.84, all executed to cover required tax withholding obligations.

Over what period did the Vera Therapeutics (VERA) tax withholding sales occur?

The trades used to cover tax withholding obligations occurred over two business days, from February 23, 2026 to February 24, 2026. This timing corresponds to the vesting of restricted stock units and was executed under the company’s equity incentive plan procedures.

How many Vera Therapeutics (VERA) shares does William D. Turner hold after the Form 4 transactions?

After the tax-related sales, William D. Turner beneficially owns 45,313 shares of Vera Therapeutics Class A common stock. This remaining stake reflects his continuing equity interest in the company following the mandatory sell-to-cover transactions for RSU tax withholding.

What does a sell-to-cover transaction mean for Vera Therapeutics (VERA) insiders?

A sell-to-cover transaction means shares are sold automatically to pay taxes on vesting equity awards. For Vera Therapeutics, the filing notes the company elected this method under its equity incentive plans, so insiders’ sales in this context are primarily administrative, tax-driven events.